ArticleeLife2022
Critical roles for 'housekeeping' nucleases in type III CRISPR-Cas immunity.
Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Cas10 residues lining the target RNA binding channel regulate interference by distinguishing cognate target RNA from mismatched targets.RNA biology · 2026Article
- Structural insights into RNA recognition by theProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Of Commensals and Opportunists: Genomics of Coagulase-Negative Staphylococci During Sequential Ear and Eye Infections in a Healthy Adult.MicrobiologyOpen · 2026Article
- A phage-encoded anti-CRISPR protein co-opts host enolase to prevent type III CRISPR immunity.Nature microbiology · 2025Article
- Carrot and stick: how RNase R contributes to function and destruction of the translation machinery.RNA biology · 2025Review
- The extended mobility of plasmids.Nucleic acids research · 2025Review
- Structural and molecular mechanisms of an Ro60 homolog from a Thermus bacteriophage.Nucleic acids research · 2025Article
- AcrIIIA1 is a protein-RNA anti-CRISPR complex that targets core Cas and accessory nucleases.Nucleic acids research · 2024Article
- RNA processing by the CRISPR-associated NYN ribonuclease.The Biochemical journal · 2024Article
- RNA targeting and cleavage by the type III-Dv CRISPR effector complex.Nature communications · 2024Article
- Genetic Engineering of Therapeutic Phages Using Type III CRISPR-Cas Systems.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Type III CRISPR-Cas: beyond the Cas10 effector complex.Trends in biochemical sciences · 2024Review
- The phage fought the cells, and the phage won: a satellite symposium at the ASV 2023 annual meeting.Journal of virology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR-Cas systems are a family of adaptive immune systems that use small CRISPR RNAs (crRNAs) and CRISPR-associated (Cas) nucleases to protect prokaryotes from invading plasmids and viruses (i.e., phages). Type III systems launch a multilayered immune response that relies upon both Cas and non-Cas cellular nucleases, and although the functions of Cas components have been well described, the identities and roles of non-Cas participants remain poorly understood. Previously, we showed that the type III-A CRISPR-Cas system in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.